Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 254

Similar articles for PubMed (Select 17014899)

1.

Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.

Karam AK, Santillan A, Bristow RE, Giuntoli R 2nd, Gardner GJ, Cass I, Karlan BY, Li AJ.

Gynecol Oncol. 2007 Feb;104(2):377-80. Epub 2006 Oct 2.

PMID:
17014899
2.

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.

Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM.

J Surg Oncol. 2000 Sep;75(1):24-30.

PMID:
11025458
3.

Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?

Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE.

Gynecol Oncol. 2010 May;117(2):336-40. doi: 10.1016/j.ygyno.2010.01.014. Epub 2010 Feb 12.

PMID:
20153027
4.

A third evaluation of tertiary cytoreduction.

Gultekin M, Velipa┼čao─člu M, Aksan G, Dursun P, Dogan NU, Yuce K, Ayhan A.

J Surg Oncol. 2008 Dec 1;98(7):530-4. doi: 10.1002/jso.21146.

PMID:
18937233
5.

The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.

Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY.

Gynecol Oncol. 2006 Dec;103(3):977-84. Epub 2006 Jul 11.

PMID:
16837030
6.

Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.

Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, Fujii S.

J Obstet Gynaecol Res. 2006 Dec;32(6):580-7.

PMID:
17100820
7.

Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.

Eisenkop SM, Friedman RL, Wang HJ.

Cancer. 1995 Nov 1;76(9):1606-14.

PMID:
8635065
8.

[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].

Yan X, An N, Jiang GQ, Gao M, Gao YN.

Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):298-301. Chinese.

PMID:
18788637
9.

Surgical cytoreduction for recurrent epithelial ovarian cancer.

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K.

Cochrane Database Syst Rev. 2013 Feb 28;2:CD008765. doi: 10.1002/14651858.CD008765.pub3. Review.

PMID:
23450588
10.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
11.

Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.

Zang RY, Zhang ZY, Li ZT, Cai SM, Tang MQ, Chen J, Liu Q.

Eur J Surg Oncol. 2000 Dec;26(8):798-804.

PMID:
11087649
12.

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.

Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE.

Cancer. 2007 Feb 15;109(4):685-91.

13.

The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).

Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.

Eur J Surg Oncol. 2009 Oct;35(10):1105-8. doi: 10.1016/j.ejso.2009.03.010. Epub 2009 May 13.

PMID:
19443175
14.

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.

Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A.

Gynecol Oncol. 2000 Dec;79(3):344-9.

PMID:
11104603
15.

Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.

Santillan A, Karam AK, Li AJ, Giuntoli R 2nd, Gardner GJ, Cass I, Karlan BY, Bristow RE.

Gynecol Oncol. 2007 Mar;104(3):686-90. Epub 2006 Dec 1.

PMID:
17141302
16.

Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.

Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR.

Anticancer Res. 2000 May-Jun;20(3B):1959-64.

PMID:
10928134
17.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
18.

Advanced ovarian cancer.

van der Burg ME.

Curr Treat Options Oncol. 2001 Apr;2(2):109-18. Review.

PMID:
12057129
19.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
20.

Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.

Leiser AL, Chi DS, Ishill NM, Tew WP.

Gynecol Oncol. 2007 Jun;105(3):657-61. Epub 2007 Mar 28.

PMID:
17395252
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk